Eikon Therapeutics, Inc. priced its initial public offering at $18.00 a share, offering 21,177,600 shares of common stock, to list on the Nasdaq Global Select Market under the symbol EIKN. It filed a Form S-1 registration statement for an initial public offering on January 9, 2026. As of November 6, 2026, its final prospectus is on file (Form 424B4, February 5, 2026).
Sell to companies like Eikon Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Eikon Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-01-09. It has amended it 1 time. It filed its final prospectus on 2026-02-05, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Eikon Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.2% of the class | 5%+ stakes | Source |
| October 2, 2026 | Stake report, Schedule 13G/A, by Abu Dhabi Investment Authority | 2.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.2% of the class | 5%+ stakes | Source |
| August 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Innovation Endeavors III LP | 5% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G, by PERLMUTTER ROGER M | 5.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 7.1% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 5.5% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G, by Abu Dhabi Investment Authority | 5.2% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13D, by The Column Group IV GP, LP | 11.6% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by James B. Tananbaum | 7.7% of the class | 5%+ stakes | Source |
Check before you invest in Eikon Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Eikon Therapeutics, Inc. and the records around it.
Eikon Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Maze Therapeutics, Inc. (Nov 2025)
- Abu Dhabi Investment Authority also filed stake reports on 7 other companies: Jersey Mike's Subs Inc. (Oct 2026), AGL Private Credit Income Fund (Sep 2026), ReNew Energy Global plc (Aug 2026)
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q1 2026, newest first.
- Clear Street Group Inc. (Feb 2026)
Watch Eikon Therapeutics, Inc.
Get an email when Eikon Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Eikon Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eikon Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eikon Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market, or Nasdaq, under the trading symbol “EIKN.”From the 424B4 filed 2026-02-05
Shares offered
This is an initial public offering of shares of common stock of Eikon Therapeutics, Inc. We are offering 21,177,600 shares of our common stock.From the 424B4 filed 2026-02-05
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-02-05
Use of proceeds
We intend to use the net proceeds to us from this offering to advance the clinical development of EIK1001, our most advanced product candidate, through (i) the ongoing Phase 2 portion of our Phase 2/3 registrational trial in advanced melanoma, (ii) completion of the full data readout of our ongoing Phase 2 trial in NSCLC, and (iii) advancement of our Phase 2/3 registrational trial in NSCLC; to advance the clinical development of EIK1003 through completion of our Phase 1/2 clinical trial, including the combination cohorts and dose optimization; to advance the clinical development of EIK1004 through completion of Part 1 of our Phase 1/2 clinical trial and initiation of Part 2 thereof; to…From the 424B4 filed 2026-02-05
Net loss or income
For the nine months ended September 30, 2025 and the years ended December 31, 2024 and 2023, we reported a net loss of $244.6 million, $243.8 million, and $242.0 million, respectively.From the S-1/A filed 2026-01-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-01-09 | Registration statement filed | S-1 |
| 2026-01-28 | Registration statement amended | S-1/A |
| 2026-02-05 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Eikon Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.